Xcellerated T CellsTM in Patients With Multiple Myeloma
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Mark W Frohlich, MD
Xcyte Therapies
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Oncotherapeutics
Los Angeles, California, United States
- University of California, San Diego
San Diego, California, United States
- University of California, San Francisco
San Francisco, California, United States
- Johns Hopkins Medical Institute
Baltimore, Maryland, United States
- Center for Cancer & Blood Disorders
Bethesda, Maryland, United States
- Washington University School of Medicine
St Louis, Missouri, United States
- Hackensack University Medical Center
Hackensack, New Jersey, United States
- Oregon Health Sciences University
Portland, Oregon, United States
- Cancer Centers of the Carolinas
Greenville, South Carolina, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Nov 2003
- Primary completion
- —
- Completion
- 30 Jun 2004
- Last update posted
- 11 Nov 2005
- Registered enrollment
- 30
- Registry id
- NCT00078065
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.